are they stopping compounded semaglutide COMPOUNDED SEMAGLUTIDE – Fitish Drug compounders sue FDA over

If you have struggled with obesity for a long time, it is not recommended that you stop taking GLP-1 medication

Weight loss of at least 5%10% is known to reduce complications of T2D and improve quality of life (Valdecantos et al., 2016)

The rise of GLP-1 receptor agonists such as Ozempic, Wegovy, Zepbound, and Mounjaro now accounts for a global pharmaceutical market share in the tens of billions of dollars annually estimated in 2024 to be $53 billion and expected to grow to $150 billion by 2030

Everything below is secondary to hitting your protein target and lifting something heavy a few times a week

In conclusion, microenvironmental heterogeneity across oncologic, metabolic, neurologic, cardiovascular, and immune-related disorders presents a pervasive and dynamic challenge for GLP-1R-targeted nanomedicines